Alkermes (ALKS) financials
Alkermes revenue and earnings by year
Alkermes's revenue was $1.48 billion in the fiscal year to December 31, 2025, down 5.2% from the year before. Net income was $242 million, 16.4% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 7.9% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.48 | 1.56 | 1.66 | 1.11 | 1.17 | 1.04 | 1.17 | 1.09 | 0.90 | 0.75 |
| Revenue growth | -5.2% | -6.4% | 49.6% | -5.3% | 13.0% | -11.3% | 7.0% | 21.1% | 21.1% | — |
| Gross profit | 1.28 | 1.31 | 1.41 | 0.89 | 0.98 | 0.86 | 0.99 | 0.92 | 0.75 | 0.61 |
| Gross margin | 86.7% | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% | 84.6% | 83.9% | 82.9% | 82.3% |
| Operating income | 0.25 | 0.42 | 0.41 | -0.01 | 0.10 | -0.11 | -0.18 | -0.10 | -0.15 | -0.21 |
| Operating margin | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% | -15.0% | -9.1% | -16.4% | -28.0% |
| Net income | 0.24 | 0.37 | 0.36 | -0.16 | -0.05 | -0.11 | -0.20 | -0.14 | -0.16 | -0.21 |
| Net margin | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% |
| Diluted EPS | $1.43 | $2.17 | $2.10 | -$0.97 | — | -$0.70 | -$1.26 | -$0.89 | -$1.03 | -$1.37 |
| Free cash flow | 0.48 | 0.37 | 0.35 | -0.02 | 0.07 | 0.04 | -0.02 | 0.03 | -0.03 | -0.11 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ALKS in Markets.
How Alkermes makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Vivitrol | $124M | 25.1% |
| Aristada & Aristada Initio | $96.7M | 19.5% |
| LUMRYZ | $96.6M | 19.5% |
| LYBALVI | $94.0M | 18.9% |
| Royalty | $63.4M | 12.8% |
| Manufacturing Revenue | $20.9M | 4.2% |
See also: ALKS valuation and P/E history · ALKS returns
No forecast, no recommendation. This page describes Alkermes from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.